Megan Lerner to Adenocarcinoma
This is a "connection" page, showing publications Megan Lerner has written about Adenocarcinoma.
Connection Strength
0.623
-
Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Invest. 2017 Oct 21; 35(9):573-585.
Score: 0.118
-
Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget. 2016 Aug 16; 7(33):53165-53177.
Score: 0.109
-
Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling. Cancer Invest. 2012 Feb; 30(2):180-8.
Score: 0.079
-
miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011 Mar 25; 406(4):518-23.
Score: 0.075
-
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007 Mar 01; 120(5):1046-54.
Score: 0.057
-
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005 Dec; 124(6):838-45.
Score: 0.052
-
DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem. 2003 Mar; 51(3):303-9.
Score: 0.043
-
Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg. 2002 Dec; 184(6):642-7; discussion 647-8.
Score: 0.042
-
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer. 1999 Sep 01; 86(5):756-63.
Score: 0.034
-
Biomarker identification in human pancreatic cancer sera. Pancreas. 2008 Jan; 36(1):61-9.
Score: 0.015